Figure 4.1 – Perinatal Hepatitis B Prevention Program: Outcomes by Birth Cohort Year

At a glance

During 2009-2020, the percentage of infants who received post-exposure prophylaxis (PEP) has remained relatively stable, between 95%-97% each year. The percentage of infants who received post-vaccination serologic testing (PVST) has increased from 59% (6,792 of 11,551 infants managed) in 2009 to 66% (4,960 of 7,583 infants managed) in 2020.
CDC 2021 Hepatitis B Surveillance Report perinatal hepatitis b prevention program

Outcomes of infants born to persons with hepatitis B and managed by the CDC Perinatal Hepatitis B Prevention Program (PHBPP), by birth cohort year — 56 US Jurisdictions,* 2009–2020

Figure 4.1
figure-4.1
Download
Download

Source: CDC, National Perinatal Hepatitis B Prevention Program (PHBPP). Infants managed: Number of infants case managed by the PHBPP.

PEP (postexposure prophylaxis): Number of infants who received PEP (hepatitis B immune globulin and 1st dose of hepatitis B vaccine) for hepatitis B virus infection.

PVST (postvaccination serological testing): Number of infants who received PVST after hepatitis B vaccine series completion.

* Includes 50 states, District of Columbia, and five cities. Excludes territories and freely associated island nations.

Summary

The number of infants whose care was managed in the CDC Perinatal Hepatitis B Prevention Program from 50 states, District of Columbia, and five cities was 11,551 in 2009 and 7,583 in 2020. During 2009-2020, the percentage of infants who received PEP has remained relatively stable between 95% to 97% each year. The percentage of infants who received PVST has increased from 59% (6,792 of 11,551 infants managed) in 2009 to 65% (4,960 of 7,583 infants managed) in 2020.

Print
Content Source:
About Division of Viral Hepatitis